Inflammatory Markers and Cognitive Function in Major Depression

• Status: Unknown status
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Major depression is accompanied by cognitive changes as well as alterations in multiple physical functions. The inflammatory system is altered generally toward a pro-inflammatory state. Antidepressants are associated with a decrease in this proinflammatory state. This study aims to generate pilot data concerning a possible link between cognition, inflammation and response to treatment. The cognitive function of subjects with major depression will be tested before and after treatment with duloxetine. Inflammatory markers will be measured at both time points.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal; Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
• Collaborator: Eli Lilly and Company
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Age 20-50 Primary diagnosis of major depression Ability to give informed consent

Exclusion Criteria:

• Neurologic disorders affecting cognition

• Unstable or untreated medical disorders

• Medical disorders associated with pain

• Recent pregnancy or delivery

• Psychiatric disorders other than MD which are the primary focus of treatment

• Treatment with antidepressants in the past 4 weeks